Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

Lignende værker

• Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
  af: Su, Po-Lan, et al.
  Udgivet: (2018)
• Is Behçet’s syndrome associated with an increased risk of ischemic heart disease? A real-world evidence in Taiwan
  af: Lin, Chun-Yu, et al.
  Udgivet: (2021)
• Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan
  af: Chun-Hui Lee, et al.
  Udgivet: (2022-05-01)
• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  af: Xu, Jianlin, et al.
  Udgivet: (2016)
• Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
  af: Yang, Szu-Chun, et al.
  Udgivet: (2021)